M
Masashi Mizokami
Researcher at Nagoya City University
Publications - 684
Citations - 37168
Masashi Mizokami is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 85, co-authored 650 publications receiving 34868 citations. Previous affiliations of Masashi Mizokami include National Institute of Advanced Industrial Science and Technology & University of Florida.
Papers
More filters
Journal ArticleDOI
Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C
Regino P. Gonzalez-Peralta,Ke-Ping Qian,Jan Y. She,Gary L. Davis,Tomoyoshi Ohno,Masashi Mizokami,Johnson Y.N. Lau +6 more
TL;DR: The findings indicate that the estimated duration of HCV carriage, serum HCV RNA levels, and HCV type 1 are important determinants for the evolution of HCVs quasispecies heterogeneity; and that increased HCV quasisPEcies heterogeneity is another marker associated with a poor subsequent response to interferon‐α.
Journal ArticleDOI
Hepatitis B Virus Genotypes and Hepatocellular Carcinoma in Japan
Etsuro Orito,Masashi Mizokami +1 more
TL;DR: Although the risk factors associated with HCC should be investigated with respect to host and environmental factors, the differences in genotypes and subtypes of HBV would need to be taken into consideration in etiological and clinical studies on HCC.
Journal ArticleDOI
Impairment of Hepatitis B Virus Virion Secretion by Single-Amino-Acid Substitutions in the Small Envelope Protein and Rescue by a Novel Glycosylation Site
Kiyoaki Ito,Yanli Qin,Michael T. Guarnieri,Tamako Garcia,Karen Kwei,Masashi Mizokami,Jiming Zhang,Jisu Li,Jack R. Wands,Shuping Tong +9 more
TL;DR: It is demonstrated that N-linked glycosylation of HBV envelope proteins is critical for virion secretion and that the secretion defect caused by mutations in the S protein can be rescued by an extra glycosolation site.
Journal ArticleDOI
Detection of Anti-Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System
Takanobu Kato,Tomoko Date,Michiko Miyamoto,Masaya Sugiyama,Yasuhito Tanaka,Etsuro Orito,Tomoyoshi Ohno,Kanji Sugihara,Izumi Hasegawa,Kei Fujiwara,Kiyoaki Ito,Atsushi Ozasa,Masashi Mizokami,Takaji Wakita +13 more
TL;DR: An accurate and sensitive replicon system is developed, and the antivirus effect of interferon and ribavirin was easily detected within their clinical concentrations by this replicons system, and this system will provide a powerful tool for screening new antiviral compounds against HCV.
Journal ArticleDOI
Antigenicities of Group I and II Hepatitis C Virus Polypeptides—Molecular Basis of Diagnosis
Kyoko Tsukiyama-Kohara,Kenjiro Yamaguchi,Noboru Maki,Yoshihiro Ohta,Keizaburo Miki,Masashi Mizokami,Ken-ichi Ohba,Satoshi Tanaka,Nobu Hattori,Akio Nomoto,Michinori Kohara +10 more
TL;DR: The results indicate that most HCV isolates can be classified into either group I or II, and that the existence of two groups of HCV does not disturb HCV diagnosis as long as core and/or NS3 peptides are used to detect HCV antibodies.